Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 1, pp 71–74 | Cite as

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study

  • D. Doll
  • M. Goutsou
  • S. Graziano
  • J. Ellerton
  • J. Bitran
  • C. Modeas
  • J. Herndon
  • M. Perry
  • M. Green
Original Articles Carboplatin, Vinblastine, Non-Small-Cell Lung Cancer


Between July 2, 1987, and August 21, 1987, Cancer and Leukemia Group B (CALGB) conducted a phase II evaluation of carboplatin (CBDCA) and vinblastine (VBL) in advanced non-small-cell lung cancer. Of the 58 patients who entered the study, 55 were eligible and produced follow-up data. Chemotherapy, which was carried out in 28-day cycles, consisted of 4 mg/m2 VBL given on days 1 and 3 and 125 mg/m2 CBDCA given on days 1–3. Partial responses were observed in 10 cases (18%), and 1 patient (2%) exhibited regression of evaluable disease. No complete responses were achieved. The overall objective response rate was 20%. The median survival was 6.1 months, and the median time to treatment failure was 3.3 months. Life-threatening (grade 4) toxicity was mainly leukopenia (20%), followed by anemia (7%), infection (4%), thrombocytopenia (2%), fever (2%), nausea and vomiting (2%), and weight loss (2%). There were two deaths due to infection. The results of this study demonstrate that the combination CBDCA/VBL is active in advanced NSCLC; however, whether this combination is more active than either CBDCA or VBL alone is unknown.


Lung Cancer Leukemia Anemia Cancer Research Median Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Blumenreich MS, Woodcock TM, Gentile PS, Barnes GV, Vose B, Sherrill EJ, Richman SP, Epremian BE, Kubota TT, Allegra JC (1987) High-dose cisplatin and vinblastine infusion with or without radiation therapy in patients with advanced non-small cell lung cancer. J Clin Oncol 5: 1725–1730Google Scholar
  2. 2.
    Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613Google Scholar
  3. 3.
    Bunn PA Jr (1989) The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 16 [Suppl]: 10–21Google Scholar
  4. 4.
    Bunn PA Jr (1989) Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 16: [Suppl]: 27–33Google Scholar
  5. 5.
    Ganz PA, Figlin RA, Haskell CM, LaSoto N, Sian J (1989) Supportive care versus supportive care and combination chemotherapy in metastatic non-small lung cancer: does chemotherapy make a difference? Cancer 63: 1271–1278Google Scholar
  6. 6.
    Gatzemeier U, Heckmayr M, Neuhauss R, Hossfeld D, Achterrath W, Lenaz L (1990) Phase II studies with carboplatin in nonsmall cell lung cancer. Semin Oncol 17 [Suppl]: 25–31Google Scholar
  7. 7.
    Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. (Wiley series in probability and mathematical statistics) John Wiley and Sons, New YorkGoogle Scholar
  8. 8.
    Kaplan EL, Meier RL (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481Google Scholar
  9. 9.
    Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, Thinlaux V, Lecomte J, Cordier R, Dabouis G, Brohée D, Thèmelin L, Mommen P (1989) Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7: 1087–1092Google Scholar
  10. 10.
    Kreisman H, Ginsberg S, Propert KJ, Richards F, Graziano S, Green M (1987) Carboplatin or iprolatin in advanced non-small cell lung cancer: a cancer and Leukemia Group B study. Cancer Treat Rep 71: 1049–1052Google Scholar
  11. 11.
    Mehta CR, Patel NR (1983) A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables. J Am Stat Assoc 78: 382, 427–434Google Scholar
  12. 12.
    Rapp E, Pater JL, Willan A, Cormièr Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub VI, Wilson KS, Latreille V, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer — report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633–641Google Scholar
  13. 13.
    Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fermandez C, Ribelles N, Culubret M (1990) A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 65: 1692–1699Google Scholar
  14. 14.
    Williams CJ, Woods R, Levi J, Page J (1988) Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine vs no chemotherapy. Semin Oncol 15 [Suppl]: 58–61Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • D. Doll
    • 9
  • M. Goutsou
    • 1
  • S. Graziano
    • 2
  • J. Ellerton
    • 3
  • J. Bitran
    • 4
  • C. Modeas
    • 5
  • J. Herndon
    • 6
  • M. Perry
    • 7
  • M. Green
    • 8
  1. 1.Department of BiostatisticsHarvard School of Public HealthBoston
  2. 2.Department of MedicineSUNY Health Science CenterSyracuse
  3. 3.Southern Nevada Cancer Research Foundation, CCOPLas Vegas
  4. 4.Department of MedicineUniversity of ChicagoChicago
  5. 5.Frontier Science Technology and Research FoundationAmhurst
  6. 6.Department of BiostatisticsDuke University Medical Center Durham
  7. 7.Department of MedicineUniversity of MissouriColumbia
  8. 8.Department of Medicine and Cancer CenterUniversity of California at San DiegoSan Diego
  9. 9.Department of MedicineUniversity of MissouriColumbiaUSA

Personalised recommendations